Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.

ABSTRACT: The global COVID-19 pandemic arising from SARS-CoV-2 has impacted many lives, gaining interest worldwide ever since it was first identified in December 2019. Till 2023, 752 million cumulative cases and 6.8 million deaths were documented globally. COVID-19 has been rapidly evolving, affecting virus transmissibility and properties and contributing to increased disease severity. The Omicron is the most circulating variant of concern. Although success in its treatment has indicated progress in tackling the virus, limitations in delivering the current antiviral agents in battling emerging variants remain remarkable. With the latest advancements in nanotechnology for controlling infectious diseases, liposomes have the potential to counteract SARS-CoV-2 because of their ability to employ differen

SUBMITTER: Mohammad Faizal NDF 

PROVIDER: S-EPMC10730353 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature